홈MCP워크벤치Skills
홈워크벤치알림마이페이지
llms.txt · MCP 가이드개인정보처리방침 · 이용약관 · 지원v1.8.3
  1. 홈
  2. /화합물

Cytisine

HCID 10235
새 반응
인쇄
기본 정보개요이름 및 식별자물성안전 및 규제화학 및 산업관련 반응화합물 노트
부분 구조 검색유사 구조 찾기

기본 정보

CAS
485-35-8
표준 SMILES
O=c1cccc2n1C[C@@H]1CNC[C@H]2C1
InChIKey
ANJTVLIZGCUXLD-DTWKUNHWSA-N
분자식
C11H14N2O
평균 분자량
190.24 g/mol
단동위원소 질량
190.11061307

개요

Cytisine is an organic heterotricyclic compound that is the toxic principle in Laburnum seeds and is found in many members of the Fabaceae (legume, pea or bean) family. An acetylcholine agonist, it is widely used throughout Eastern Europe as an aid to giving up smoking. It has a role as a phytotoxin, a nicotinic acetylcholine receptor agonist and a plant metabolite. It is an alkaloid, a lactam, an organic heterotricyclic compound, a bridged compound and a secondary amino compound.

이름 및 식별자

우선 이름
Cytisine
IUPAC
(1R,9S)-7,11-diazatricyclo[7.3.1.02,7]trideca-2,4-dien-6-one
영어명
CYTISINE
분자식
C11H14N2O
분자량
190.24

이름 및 동의어

CYTISINE485-35-8BaptitoxineCytisiniclineSophorineBaptitoxinCytitonLaburninUlexineUlexinCytitoneCitizin
이름 더 보기
CytisinTabax(-)-CytisineCytisinicline/Cytisin (6039-Sopharma)
CystisineCytizin(1r,5s)-1,2,3,4,5,6-Hexahydro-8h-1,5-Methanopyrido[1,2-A][1,5]diazocin-8-One6039 SopharmacitisiniclinaNSC-407282(1R,9S)-7,11-diazatricyclo[7.3.1.02,7]trideca-2,4-dien-6-one53S5U404NU

데이터베이스 식별자

CAS
485-35-8
PubChem CID
10235
DTXSID
DTXSID00883395
ChEMBL
CHEMBL497939
ChEBI
CHEBI:4055
UNII
53S5U404NU
EC Number
207-616-0
Nikkaji
J9.571K

물성

구조 계산 물성

XLogP
0.2
극성 표면적
32.3 Ų
수소 결합 공여자 수
1
수소 결합 수용자 수
2
회전 가능 결합 수
0
무거운 원자 수
14
형식 전하
0
복잡도
332

실험 및 물리화학적 성질

DrugsPharmaceuticals -> Listed in ZINC15
Color/Form · 2건

Orthorhombic prisms from acetone

Solid

Solubility · 3건

Soluble in 13 parts acetone, 1.3 parts methanol, 3.5 parts alcohol, 30 parts benzene, 10 parts ethyl acetone, 2.0 parts chloroform; practically insoluble in petroleum ether

Soluble in 1.3 parts water

In water, 4.39X10+5 mg/L at 16 °C

Boiling PointBP: 218 °C at 2 mm Hg
DecompositionWhen heated to decomposition it emits toxic fumes of /nitrogen oxides/.
Melting Point · 3건

152-153

152-153 °C (sublimes)

MP: 155 °C

Optical Rotation · 2건

Needles or leaflets. Specific optical rotation: -81.5 deg at 25 °C/D; soluble in water, slightly soluble in alcohol; practically insoluble in ether /Cytisine nitrate monohydrate/

Specific optical rotation: -120 deg at 17 °C/D

Dissociation ConstantspK1 = 6.11; pK2 = 13.08

안전 및 규제

안전 정보는 참고용이며, 공급업체의 물질안전보건자료(SDS), 관련 법규 및 전문가 평가를 대체하지 않습니다.

GHS 분류

GHS Classification · 4건

Danger

H301 (100%): Toxic if swallowed [Danger Acute toxicity, oral]

P261, P264, P264+P265, P270, P271, P280, P301+P316, P302+P352, P304+P340, P305+P351+P338, P319, P321, P330, P332+P317, P337+P317, P362+P364, P403+P233, P405, and P501 (click each P-code to see the statement)

Aggregated GHS information provided per 76 reports by companies from 10 notifications to the ECHA C&L Inventory. Each notification may be associated with multiple companies.

유해성 정보

Regulatory Information · 2건

Regulation (EC) No 178/2002 (amended)

1,5-Methano-8H-pyrido1,2-a1,5diazocin-8-one, 1,2,3,4,5,6-hexahydro-, (1R,5S)-: Does not have an individual approval but may be used under an appropriate group standard

Hazard Classes and CategoriesAcute Tox. 3 (100%)

안전 및 보호

Storage ConditionsIn original packages, in dry, and light-protected premises at temperature of 15 °C to 25 °C (60 - 75 °F)
Disposal Methods · 1건

SRP: The most favorable course of action is to use an alternative chemical product with less inherent propensity for occupational harm/injury/toxicity or environmental contamination. Recycle any unused portion of the material for its approved use or return it to the manufacturer or supplier. Ultimate disposal of the chemical must consider: the material's impact on air quality; potential migration in soil or water; effects on animal and plant life; and conformance with environmental and public health regulations.

독성 정보

화학 및 산업

약리 정보

ATC Code · 2건

N - Nervous system

QN - Nervous system

Pharmacodynamics · 1건

Various models have been run where the affinity of nAChR agonists to the receptor subtype are tested to help identify the molecules, groups and steric conformation that are vital to greater affinity. By using a nAChR muscle receptor subtype (α1)2β1δγ model the following results were obtained: anatoxin > epibatidine > acetylcholine > DMPP >> CYTISINE > pyrantel > nicotine > coniine > tubocurare > lobeline, where anatoxin had the highest activity efficacy and tubocurare the lowest. Acetylcholine on the other hand induced a much longer opening time of the receptor though anatoxin is more potent. The results suggest that anatoxin derivatives would be helpful in understanding structure-activity relationships (SAR) for muscle nAChRs (Cooper et al., 1996).

Mechanism of Action · 6건

Cytisine is a low efficacy partial agonist of ⍺4-β2 nicotinic acetylcholine receptors. These which are believed to be central to the effect of nicotine (NIC) on the reward pathway and facilitate addiction. Cytisine reduces the effects of NIC on dopamine release in the mesolimbic system when given alone, while simultaneously attenuating NIC withdrawal symptoms that accompany cessation attempts.

Cytisine is an agonist of the cholinoreceptors in the vegetative ganglia and belongs to the group of the gangliostimulating drugs. It excites the nicotine-sensitive cholinoreceptors of the postsynaptic membranes in the vegetative ganglia, chromaffin cells in the molecular part of the suprarenal gland and sinocarotid reflexogenic zone, which results in excitation of the respiratory center, predominantly through the reflexes, simulation of adrenaline release by the medullar part of the suprarenal glands and a rise in the blood pressure. After its absorption in the gastrointestinal tract, cytisine plays the part of a nicotine-substitute substance which decreases the period of interaction between nicotine and the corresponding receptors. This in turn leads to a gradual decrease and interruption of the smokers' psychic and physical nicotine dependence.

A family of genes has been identified that encodes subunits of nicotinic acetylcholine receptors (nAChRs) and is expressed in the nervous system. Functional neuronal nAChRs can be expressed in Xenopus oocytes by injection of RNA encoding 1 of 2 different beta-subunits (beta 2, beta 4) in pairwise combination with RNA encoding 1 of 3 different alpha-subunits (alpha 2, alpha 3, alpha 4). We examined the sensitivity of these 6 different alpha- beta-subunit combinations to the nicotinic agonists ACh, nicotine, cytisine, and 1,1-dimethyl-4-phenylpiperazinium (DMPP). Each subunit combination displayed a distinct pattern of sensitivity to these 4 agonists. The alpha 2 beta 2 combination was 5-fold more sensitive to nicotine than to acetylcholine, while the alpha 3 beta 2 combination was 17-fold less sensitive to nicotine than to ACh, and the alpha 3 beta 4 combination was equally sensitive to both nicotine and ACh. nAChRs composed of alpha 2, alpha 3, or alpha 4 in combination with beta 2 were 14-100-fold less sensitive to cytisine than to ACh. In contrast, nAChRs composed of alpha 2, alpha 3, or alpha 4 in combination with beta 4 were 3-17-fold more sensitive to cytisine than to ACh. The alpha 2 beta 2, alpha 3 beta 2, and alpha 3 beta 4 combinations were each equally sensitive to DMPP and ACh, while the alpha 2 beta 4, alpha 4 beta 2, and alpha 4 beta 4 combinations were 4-24-fold less sensitive to DMPP than to ACh. We also demonstrated that these differences are neither a consequence of variation in the relative amounts of RNA injected nor an artifact of oocyte expression. The oocyte system can accurately express ligand-gated ion channels because mouse muscle nAChRs expressed in oocytes display pharmacological properties similar to those reported for these receptors expressed on BC3H-1 cells. We conclude that both the alpha- and the beta-subunits contribute to the pharmacological characteristics of neuronal nAChRs.

관련 반응

3건
반응 기록 만들기
HRID 986921 반응식
HRID 986921반응물로
HRID 1977595 반응식
HRID 1977595반응물로
HRID 2230905 반응식
HRID 2230905반응물로

화합물 노트

이 페이지에서기본 정보개요이름 및 식별자물성안전 및 규제화학 및 산업관련 반응화합물 노트
Collision Cross Section · 2건

137.9 Ų [M+H]+ [CCS Type: TW; Method: calibrated with polyalanine and drug standards]

136.73 Ų [M+H]+ [CCS Type: TW; Method: calibrated with polyalanine and drug standards]

Other Experimental PropertiesDeliquescent crystals, soluble in water and alchol. pH of 0.1 molar aqueous solution = 4.3 /Cytisine hydrochloride/

물리화학적 성질

녹는점
154 · 154-156 °C (lit.)
끓는 점
218 °C/2 · 218 °C/2 mmHg (lit.)
밀도
1.0815 · 1.0815 (rough estimate)
굴절률
1.57 · 1.5700 (estimate)
저장 조건
2 · Keep in dark place,Sealed in dry,2-8°C
용해도
439 · 439그램/리터
산도 계수 (pKa)
6.11 · 6.11, 13.08(at 25℃)
물리적 상태
가루
색상
연노랑
수용성
439 g/L · 439g/L(16ºC)
Merck
14 · 14,2789
InChI
1S/C11H14N2O/c14-11-3-1-2-10-9-4-8(5-12-6-9)7-13(10)11/h1-3,8-9,12H,4-7H2/t8-,9+/m0/s1
InChIKey
ANJTVLIZGCUXLD-DTWKUNHWSA-N
SMILES
O=C1C=CC=C2C3CNCC(C3)CN12
LogP
0.172 · 0.172 (est)
NIST
Cytisine(485-35-8)
EPA
Cytisine (485-35-8)

화학적 성질

Off-White to Tan Crystalline Solid

Interactions · 2건

The analeptic effect of cytisine decreases during combined therapy with antituberculosis drugs (PASA, streptomycin, etc.).

The effect of various drugs on the acute toxicity of cytisine, the toxic constituent of Laburnum anagyroides Med, was studied in mice. Drugs were tested which have been recommended for symptomatic treatment of laburnum poisoning. Drugs which influence the CNS reduce the acute toxicity of cytisine more effectively than those with predominantly peripheral site of action.

Plant ConcentrationsCytisine detections in various plants(1).[Table#4635]
Natural Pollution Sources · 2건

Cytisine is a toxin found in some plants(1,2). It is the toxic principle in seed of Laburnum anagyroides Medik /golden chain tree/, and other Leguminosae(3).

Nicotinic receptor in the nervous system of organisms

Human Toxicity Excerpts · 3건

/SIGNS AND SYMPTOMS/ Symptoms of nicotine intoxication are observed in /cytisine/ overdose. The toxic effects are manifested in nausea, vomiting, pupil dilation, tachycardia, general weakness, clonic convulsions, paralysis of respiration. The communications of overdose with the drug are scarce.

/ALTERNATIVE and IN VITRO TESTS/ The nicotinic receptor proteins and gene transcripts for the different nicotinic receptor subunits exist in human prenatal brain already at 4-5 weeks of gestation. The early presence of nicotinic receptors suggests an important role for these receptors in modulating dendritic outgrowth, establishment of neuronal connections and synaptogenesis during development. When measurements of nicotinic receptors using [(3)H]epibatidine (labelling both the alpha3 and alpha4 subtype) and [(3)H]cytisine (labelling the alpha4 subtype) were performed in intact cells from the cortex, subcortical forebrain and mesencephalon (7.5-11 weeks of gestation), the highest specific binding for both ligands was detected in cells from mesencephalon, followed by subcortical forebrain and cortex. The effects of nicotine exposure were studied in primary cultures of prenatal brain (7.5-11 weeks of gestation). Treatment with nicotine (1-100 microM) for 3 days significantly increased the specific binding of [(3)H]epibatidine and [(3)H]cytisine in cortical cells but not in cells from subcortical forebrain and mesencephalon brain regions, indicating region-specific differences in the sensitivity to nicotine exposure. Relative quantification of mRNA showed that the expression of the nicotinic receptor subunits alpha3 and alpha7, but not alpha4, was increased in cortical cells after nicotine treatment. These findings support the assumption of a potential risk of disturbance in the functional role of nicotinic receptors during brain development as a consequence of maternal smoking during pregnancy.

/OTHER TOXICITY INFORMATION/ Cytisine has a molecular structure somewhat similar to that of nicotine and varenicline. The concept for the new smoking cessation drug varenicline was based partly on cytisine. Like varenicline, cytisine is a partial agonist of nicotinic acetylcholine receptors, with high affinity for alpha4beta2 receptors. Cytisine has been used since the 1960s as a smoking cessation drug in Eastern and Central Europe, but has remained largely unnoticed elsewhere. Three placebo-controlled trials, conducted in East and West Germany in the 1960s and 1970s, suggest that cytisine, even with minimal behavioural support, may be effective in aiding smoking cessation. Cytisine tablets are very inexpensive to produce and could be a more affordable treatment than nicotine replacement, bupropion and varenicline. There is however a dearth of scientific research on the properties of cytisine, including safety, abuse liability and efficacy. This paper seeks to identify research priorities for molecular, animal and clinical studies. In particular, new studies are necessary to define the nicotinic receptor interaction profile of cytisine, to establish its pharmacokinetics and pharmacodynamics in humans, to determine whether animals self-administer cytisine, and to ascertain whether cytisine is safe and effective as a smoking cessation drug. Potentially, this research effort, contributing to wider use of an inexpensive drug, could save many lives.

Non-Human Toxicity Excerpts · 5건

/LABORATORY ANIMALS: Acute Exposure/ In dogs, injected subcutaneously with /cytisine dose of/ 4 mg/kg, the changes occurred one hour after the treatment. The animals began vomiting, colonic and tonic convulsions of body and limbs muscles appeared. The movement was slow and phlegmatic. When stimulated by force, they became aggressive. On the following day the animals restored their normal behavior. No lethality was noted. After oral administration of doses of 15-25 mg/kg, the dogs showed no external symptoms of toxicity.

/BEHAVIORAL STUDIES/ In rats, in a 2-bar operant conditioning procedure, nicotine-appropriate responding was detected as early as 2.5 min after injection, it was maximum at 5-20 min, and disappeared after 80-160 min. Cytisine (0.4-3.2 mg/kg) increased drug-appropriate responding in a dose-related manner.

/BEHAVIORAL STUDIES/ The effects of nicotinic receptor agonists on the elevated plus-maze test of anxiety were investigated in CD1 mice after intraperitoneal injections. Nicotine and lobeline, but not cytisine, exhibited a significant increase in the time spent by the mice in the open arms, a measure of anxiolytic activity. Nicotine also increased the total number of arm entries, a measure of general activity, but this effect was secondary to its anxiolytic-like properties. Nicotinic receptor antagonists on their own did not modify the behavior of mice in the maze. The effect of nicotine was mediated by central nicotinic receptors as it was blocked by the centrally-acting nicotinic antagonists mecamylamine and chlorisondamine, but not by hexamethonium (a peripherally acting blocker). Cotinine, the major metabolite of nicotine, was evaluated at different times after systemic injections and had no effect in the plus-maze. The anxiolytic-like profile induced by nicotinic receptor stimulation was not associated with potentiation of alcohol effects, a liability associated with the benzodiazepine therapy. This study demonstrates the anxiolytic-like properties of nicotine and lobeline in mice, and suggests that central nicotinic receptors are involved in the expression of emotional behavior.

/ALTERNATIVE and IN VITRO TESTS/ /Investigators/ examined the effects of nicotinic receptor agonists against beta amyloid (Abeta) cytotoxicity to rat cortical neurons. Administration of nicotine protected against Abeta-induced neuronal death. This neuroprotection was blocked by dihydro-beta-erythroidine, an alpha4beta2 nicotinic receptor antagonist. Furthermore, incubation with cytisine, a selective alpha4beta2 nicotinic receptor agonist, inhibited Abeta cytotoxicity. These results suggest that alpha4beta2 nicotinic receptor activation plays an important role in neuroprotection against Abeta cytotoxicity.

For more Non-Human Toxicity Excerpts (Complete) data for CYTISINE (10 total), please visit the HSDB record page.

Antidote and Emergency Treatment · 5건

Maintain an open airway and assist ventilation if necessary. Administer supplemental oxygen. Treat seizures, coma, hypotension, hypertension, and arrhythmias if they occur. Observe for at least 4 to 6 hours to rule out delayed toxicity, especially after skin exposure. For ingestion of intact gum, tablets, or transdermal patches, observe for a longer period (up to 12-24 hours). Mecamylamine (Inversine) is a specific antagonist of nicotine actions; however it is available only in tablets, a form not suitable for a patient who is vomiting, convulsing, or hypotensive. Signs of muscarinic stimulation (eg, bradycardia, salivation, wheezing), if they occur, may respond to atropine. /Nicotine/

Decontamination. Caution: Rescuers should wear appropriate skin protective gear when treating patients with oral or skin exposures to liquid nicotine. Skin and eyes. Remove all contaminated clothing and wash exposed skin with copious soap and water. Ingestion. Administer activated charcoal only if conditions are appropriate. Gastric lavage is not necessary after tobacco ingestion if activated charcoal can be given promptly. Consider gastric lavage for large recent ingestions of liquid nicotine. For asymptomatic small-quantity cigarette ingestions, no gut decontamination is necessary. For ingestion of transdermal patches or large amounts of gum, consider repeat doses of charcoal and whole-bowl irrigation. Enhanced elimination. These procedures are not likely to be useful because the endogenous clearance of nicotine is high., its half-life is relatively short (2 hours), and the volume of distribution is large. /Nicotine/

As antidotes at overdose /for/ cytisine one may use tranquilizers (anticonvulsive effect) and antihypertensive drugs (decrease of the blood pressure).

/SRP:/ Immediate first aid: Ensure that adequate decontamination has been carried out. If patient is not breathing, start artificial respiration, preferably with a demand valve resuscitator, bag-valve-mask device, or pocket mask, as trained. Perform CPR if necessary. Immediately flush contaminated eyes with gently flowing water. Do not induce vomiting. If vomiting occurs, lean patient forward or place on the left side (head-down position, if possible) to maintain an open airway and prevent aspiration. Keep patient quiet and maintain normal body temperature. Obtain medical attention. /Poisons A and B/

For more Antidote and Emergency Treatment (Complete) data for CYTISINE (6 total), please visit the HSDB record page.

Non-Human Toxicity Values · 4건

LD50 Cat iv 400 ug/kg

LD50 Mouse iv 1730 ug/kg

LD50 Mouse ip 9400 ug/kg

LD50 Mouse oral 101 mg/kg

안전 데이터

wgk
3
tsca
TSCA listed
rtecs
HA4025000
ridadr
UN 2811 6.1/PG 3
독성
LD50 in mice (mg/kg): 1.73 i.v.; 9.4 i.p.; 101 orally (Barlow, McLeod)
HS 번호
29399990
risk_code
25-36/37/38
hazard_code
T
safety_code
26-28-36/37-45
포장분류
III
위험 등급
6.1(b)
Hazard Classifications
Acute Tox. 3 DermalAcute Tox. 3 InhalationAcute Tox. 3 Oral
스토리지 클래스
6.1C - Combustible acute toxic Cat.3toxic compounds or compounds which causing chronic effects
유해 물질 데이터
485-35-8(Hazardous Substances Data)

Neuronal nicotinic acetylcholine receptors subserve predominantly modulatory roles in the brain, making them attractive therapeutic targets. Natural products provide key leads in the quest for nicotinic receptor subtype-selective compounds. Cytisine, found in Leguminosae spp., binds with high affinity to alpha4beta2* nicotinic receptors. We have compared the effect of C3 and C5 halogenation of cytisine and methylcytisine (MCy) on their interaction with native rat nicotinic receptors. 3-Bromocytisine (3-BrCy) and 3-iodocytisine (3-ICy) exhibited increased binding affinity (especially at alpha7 nicotinic receptors; Ki approximately 0.1 microM) and functional potency, whereas C5-halogenation was detrimental. 3-BrCy and 3-ICy were more potent than cytisine at evoking (3)H dopamine release from striatal slices (EC50 approximately 11 nM), (3)H noradrenaline release from hippocampal slices (EC50 approximately 250 nM), increases in intracellular Ca2+ in PC12 cells and inward currents in Xenopus oocytes expressing human alpha3beta4 nicotinic receptor (EC50 approximately 2 microM). These compounds were also more efficacious than cytisine. C3-halogenation of cytisine is proposed to stabilize the open conformation of the nicotinic receptor but does not enhance subtype selectivity.

Cytisine, a partial agonist that binds with high affinity to the alpha4beta2 nicotinic acetylcholine receptor...

For more Mechanism of Action (Complete) data for CYTISINE (7 total), please visit the HSDB record page.

Biological Half-Life · 2건

4.8 hours.

... The absorption rate is approximately 42%. From the blood level after intravenous administration a half-life of 200 min was calculated.

Absorption, Distribution and Excretion · 4건

Oral: 6.2 l/kg Oral (5 mg/kg; tested in rabbits).

Renal: 43 mL/min.

The pharmacokinetic behavior of cytisine was studied in mice by means of tritiated cytisine after intravenous and oral administration of a sublethal dose of 2 mg/kg. After oral administration the maximum blood level is reached after 2 hr. The absorption rate is approximately 42%. From the blood level after intravenous administration a half-life of 200 min was calculated. Within 24 hr after intravenous administration 32% and after oral administration 18% of the administered radioactivity was excreted into urine. Following intravenous administration 3% of the dose was found in the feces within 6 hr. Among the examined organs and tissues the highest concentrations were reached in the liver, adrenals and kidneys. In the bile the highest concentration after intravenous administration was 200 times that in the blood.

Experimental study of pharmacokinetics of transdermal system with cytisine in rabbits showed a possibility of controlled intake of the drug over a 4-day period. The two stages of attaining the stationary levels of cytisin concentrations are revealed. The first stage lasted during first 24 hr and the second stage during succeeding 3 days. Using the data on intravenous cytisine injection we found that the stationary concentrations and the rate of cytisine intake in the first stage is twice as large as in the second stage. Thus cytisine can be classed as a short-living drug.

용도 및 제조

Uses · 2건

Formerly used as an antitussive and antiemetic

MEDICATION

Methods of Manufacturing · 2건

Cytisine was obtained from Laburnum anagyroides by extraction of the powdered dry seeds with ethyl alcohol-hydrochloric acid, distillation of the alcohol, dilution with water, filtration, and precipitation of the alkaloid with Mayer's reagent.

The isolation and identification of cytisine is described.

Formulations/PreparationsTabex: Film tablets of 1.5 mg in packages of 100.
General Manufacturing Information · 3건

1,5-Methano-8H-pyrido[1,2-a][1,5]diazocin-8-one, 1,2,3,4,5,6-hexahydro-, (1R,5S)-: ACTIVE

Toxic principle in seed of Laburnum anagyroides Medik /golden chain tree/, and other Leguminosae.

Tabex contains cytisine and is used to aid chronic smokers in abstaining from smoking. Total abstentation occurred in 65.1% of the subjects.

응용 분야 · 4건

개요It is an alkaloid that occurs naturally in several plant genera, such as Laburnum and Cytisus of the family Fabaceae. Pi-Zhen-Ye-Huang-Hua (Thermopsis lanceolata R.Br) contains large amount of cytisine, and it is distributed in the northeast, north, and northwest of China. This herb has been traditionally used for treating cough in China and was recorded in “Yue-Wang-Yao-Zhen,”“Jing-ZhuBen-Cao,”“Zhong-Hua-Ben-Cao,” and “Ning-Xia-Zhong-Cao-Yao-Shou-Ce.”

역사The largest amount of cytisine (about 1–5%) is also found in the seeds of common garden decorative plant Du-Dou (Laburnum anagyroides). In the early twentieth century, cytisine was identified as the toxic component of this plant. The extracts of Laburnum seeds or flowers have been used in traditional medicine for hundreds of years. In the Second World War, the leaves of Laburnum anagyroides were used as a tobacco substitute by soldiers. In 1960s, cytisine was firstly used as a smoking cessation aid in Bulgaria. The pharmacological and clinical studies of cytisine were also conducted in other Eastern European countries such as Poland and Russia. These results were promising. Stoyanov S. and Yanachkova M. studied 70 volunteers with a long experience in smoking. They found that 57% volunteers stopped smoking and 31.4% volunteers decreased cigarettes: reduction of the cigarettes smoked from 20–30 to 3–4 a day. Cytisine was developed and marked as Tabex (Sopharma, Bulgaria), which has been widely distributed in the Eastern Europe .

용도Cytisine occurs in the seeds of Cytisus labur num L. and other Leguminosae.

일반 설명Cystine ((1R,5S)-1,2,3,4,5,6-hexahydro-1,5-methano-8H-pyrido[1,2a][1,5]diazocin-8-one) displays classical antidepressant action in various animal models of antidepressant efficacy. Infrared and Raman spectral studies suggest that it has two stable conformers.

상·하류 제품 정보

하류 제품

1,5-Methano-8H-pyrido(1,2-a)(1,4)diazocin-8-one, 3-(3-butenyl)-1,2,3,4 ,5,6-hexahydro-, (1R)-N-포르밀시티신
추가 설명 · 1건

정의ChEBI: An organic heterotricyclic compound that is the toxic principle in Laburnum seeds and is found in many members of the Fabaceae (legume, pea or bean) family. An acetylcholine agonist, it is widely used throughout Eastern Europe as n aid to giving up smoking.